Microplate Dx Limited
United Kingdom
- Glasgow, Lanarkshire
- 12/09/2023
- Seed
- $3,117,000
Microplate Dx Limited specialises in rapid antibiotic susceptibility testing diagnostics, enabling clinicians, at the point-of-care, to confidently select the best choice of antibiotic to treat a patient’s infection in a matter of minutes, significantly quicker than the current gold standard technology which takes at least 2 days. Our award-wining, platform diagnostic test helps reduce the major global health threat of antimicrobial resistance and ultimately, saves lives.
- Industry Medical Equipment Manufacturing
- Website https://microplatedx.com/
- LinkedIn https://www.linkedin.com/company/microplate-dx-limited/about/
Related People
Stuart HannahFounder
United Kingdom -
Greater Glasgow Area
CEO - Microplate Dx Limited.
Developing a rapid, cost-effective, direct-from-sample, antibiotic susceptibility test, which quickly identifies the best choice of antibiotic for a particular infection in minutes, significantly quicker than the current gold standard of days.
SPARK Microsystems | $12,364,525 | (Mar 24, 2026)
Meadow Memorials | $9,000,000 | (Mar 24, 2026)
Oryon Cell Therapies | $21,000,000 | (Mar 24, 2026)
Hamilton AI | $7,500,000 | (Mar 24, 2026)
Flourish Care | $5,700,000 | (Mar 24, 2026)
Interloom | $16,500,000 | (Mar 24, 2026)
eternal.ag | $9,271,160 | (Mar 24, 2026)
EGIDE | $9,266,200 | (Mar 24, 2026)
Cleavr | $1,158,600 | (Mar 24, 2026)
JAAQ | $17,416,100 | (Mar 24, 2026)
CisLunar Industries | $2,600,000 | (Mar 24, 2026)
Ezra AI Labs | $3,200,000 | (Mar 20, 2026)